Tizona Therapeutics, Inc., is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases.

Our Approach

Tizona develops next-generation immunotherapies

The successful development of immunotherapies represents one of the most important and exciting breakthroughs in cancer. Recent approvals of checkpoint inhibitors provide evidence that the immune system is capable of recognizing cancerous cells and eradicating them. These checkpoint inhibitors can achieve complete, durable remissions and help patients live longer. Yet, despite this progress, existing immunotherapies are effective in a relatively small number of patients and types of cancer.

Tizona’s therapies are designed to modulate the activity of immunosuppressive cells, thereby activating the body’s ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases. Our programs target the cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment and for controlling self-reactivity in autoimmunity:

  • Immune suppressive cells, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tolerogenic dendritic cells (DCs)
  • Inhibitory / suppressive cytokines and metabolic pathways

Our distinct approach to Tumor Immunotherapy

Conventional Immunotherapy Approaches
T cell Priming, Activation & Proliferation
  • Checkpoint inhibitors (e.g., CTLA4, PD-1)
  • Coactivators (e.g., 4-1BB)
  • Vaccines (peptide, DNA, DC, artificial APCs, etc.)
  • Oncolytic Viruses
  • Cytokines (IL-12, IL-15, IL-21)
Tizona’s
Current Approach
Immunosuppressive Tumor Microenvironment
  • Tregs
  • TAMs, MDSCs, tolerogenic DCs
  • Inhibitory cytokines
Opportunistic
Area of Interest
T cell Trafficking & Infiltration
  • Chemokines
  • Immuno-repellent factors

Our Team

Tizona’s expert team of scientific advisors, board of directors and accomplished team position the company to become a leader in next generation immunotherapy development.

Pablo J. Cagnoni, M.D.
President & Chief Executive Officer
Pablo is President and CEO of Tizona. Over of the course of his career as an oncologist and pharmaceutical executive, Pablo has been committed to advancing the development of breakthrough treatments for patients with cancer and other debilitating diseases.  Full Bio

Jeremy Bender, Ph.D., M.B.A.
Chief Operating Officer
Jeremy joined Tizona as COO in July of 2015.  Full Bio

Courtney Beers, Ph.D.
Vice President, Immunology
Courtney is the Vice President of Cancer Immunotherapy for Tizona. She is leading discovery and development work on Tizona’s immuno-oncology and autoimmunity programs.  Full Bio

John Corbin, Ph.D.
Vice President, Antibody Development
John joined Tizona as Vice President of Antibody Development in 2016. In his role, he is responsible for antibody discovery and engineering. Prior to joining Tizona, John was at Gilead Sciences, where he oversaw antibody discovery and engineering.  Full Bio

Svetlana Lucas, Ph.D.
Vice President, Business Development
Svetlana joined Tizona Therapeutics as Vice President of Business Development in July of 2015. In her role, she is responsible for the company’s business development strategy and transactions.  Full Bio


Board of Directors

News

Careers

April 26, 2017

Scientist, Immuno-Oncology

Summary

Tizona Therapeutics, Inc., an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases, is seeking...

Investors